Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SmarT plus PD-1 antibody and chemotherapy versus PD-1 antibody plus chemotherapy for first-line HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2200061306Phase 2Recruiting
- Sponsor
- Comprehensive Cancer Centre of Drum Tower Hospital, Nanjing University
- Start
- Jun 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of aniracetam, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Comprehensive Cancer Centre of Drum Tower Hospital, Nanjing University. Primary endpoints: Objective response rate, Progression-free survival and 2 more. Started Jun 2022; status: recruiting.
02
Drugs
aniracetamoxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200061306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061306.